低剂量艾司洛尔减轻脓毒症诱导的心肌损伤:与改善自噬稳态和PI3K/Akt信号相关
该研究结合人类外周血转录组数据集(GSE28750、GSE232753、GSE134347、GSE185263)与大鼠脓毒症心肌数据集(GSE125042)进行生物信息学分析,并在Sprague-Dawley大鼠CLP模型中于造模后4h开始输注低剂量(5 mg·kg⁻¹·h⁻¹)或高剂量(15 mg·kg⁻¹·h⁻¹)艾司洛尔。结果示低剂量艾司洛尔降低心动过速15-20%而不引起低血压,保留左室射血分数,降低cTnI(1.36至0.14 ng/mL)与脓毒症评分(18.50至8.50),改善144h生存(P=0.005);高剂量致持续低血压且无生存获益。机制上低剂量艾司洛尔部分恢复PI3K/Akt磷酸化、增强TFEB核转位、减少LC3/p62共定位,提示改善自噬体-溶酶体处理。
要点
- CLP后4h起低剂量艾司洛尔5 mg·kg⁻¹·h⁻¹输注,心率降低15-20%且不出现低血压,高剂量15 mg·kg⁻¹·h⁻¹则致持续低血压。
- 低剂量艾司洛尔组cTnI由1.36降至0.14 ng/mL、脓毒症评分由18.50降至8.50,144h生存改善(P=0.005)。
- 高剂量艾司洛尔缺乏生存获益,提示剂量选择是关键,不能将研究方案剂量外推为通用推荐。
- 机制上低剂量艾司洛尔部分恢复PI3K/Akt磷酸化、增强TFEB核转位、减少LC3/p62共定位,提示改善自噬体-溶酶体处理。
- 氯喹加重心肌损伤与自噬标志物蓄积,低剂量艾司洛尔可部分减轻氯喹所致恶化。
适用人群与场景
- Sprague-Dawley大鼠行盲肠结扎穿孔(CLP)建立的脓毒症心肌损伤模型,于CLP后4h开始给药,统一终点为CLP后18h。
- 人类外周血转录组数据来自GSE28750、GSE232753、GSE134347、GSE185263数据集,大鼠脓毒症心肌转录组来自GSE125042。
- 原文未提及急诊或ICU患者的前瞻性纳入/排除人群。
诊断标准与关键阈值
- 脓毒症心肌损伤以脓毒症评分、cTnI、左室射血分数及心脏超声评估,原文未给出诊断界值。
- 低AKT1表达与脓毒症患者较差生存相关,预后评估AUC=0.750,属中等预后性能。
- 原文未提及启动或停止艾司洛尔的临床阈值。
处置流程与药物剂量
- 第一步:大鼠CLP造模后4h开始艾司洛尔输注。
- 第二步:低剂量组按5 mg·kg⁻¹·h⁻¹输注,高剂量组按15 mg·kg⁻¹·h⁻¹输注;原文未提及给药途径与疗程细节。
- 第三步:监测心率、血压、左室射血分数、cTnI与脓毒症评分;低剂量组心率降低15-20%且无低血压。
- 自噬调控使用雷帕霉素、3-甲基腺嘌呤(3-MA)或氯喹,原文未给出剂量。
红旗征与不能漏的情况
- 高剂量艾司洛尔(15 mg·kg⁻¹·h⁻¹)引起持续低血压且无生存获益,提示剂量过高风险。
- 氯喹加重心肌损伤与自噬标志物蓄积,低剂量艾司洛尔仅部分减轻氯喹所致恶化。
- 原文未提及其他需立即处理或不能漏诊的红旗征。
研究设计与关键结果
- 研究类型为生物信息学分析联合大鼠CLP模型实验;人类数据集4个、大鼠心肌数据集1个;原文未提及样本量与中心数。
- 低剂量艾司洛尔降低心动过速15-20%且不引起低血压,保留左室射血分数,cTnI由1.36降至0.14 ng/mL,脓毒症评分由18.50降至8.50,144h生存改善(P=0.005)。
- 高剂量艾司洛尔致持续低血压且缺乏生存获益。
- 低剂量艾司洛尔部分恢复PI3K/Akt磷酸化、增强TFEB核转位、减少LC3/p62共定位,改善心房线粒体肿胀与心室肌原纤维排列紊乱。
- 低AKT1表达与脓毒症患者较差生存相关,AUC=0.750;大鼠心肌转录组示脓毒症期间PI3K/mTOR组分无转录抑制。
证据类型、等级与局限
- 证据类型为临床数据集生物信息学分析联合动物实验(大鼠CLP模型),原文未给出证据等级或推荐强度。
- 局限:未进行自噬流直接定量测定、未做通路特异性功能缺失实验、缺乏PI3K亚型特异性证据,因果关系无法确证;属临床前研究。
对床旁实践的改变
- 该临床前结果支持进一步评估低剂量艾司洛尔作为脓毒性心肌病辅助治疗的候选方案,但不能直接改变当前急诊/ICU实践。
- 剂量相关:低剂量(5 mg·kg⁻¹·h⁻¹)与高剂量(15 mg·kg⁻¹·h⁻¹)结局不同,高剂量致持续低血压,提示临床使用时需警惕剂量过高。
- 常见陷阱:不能将动物模型中的方案剂量外推为通用推荐,也不能将相关性结果当作决策阈值。
指南或共识出处
- 原文未提及指南或共识出处;来源为J Intensive Care发表的动物实验联合生物信息学研究。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sepsis-induced myocardial injury (SIMI) contributes substantially to sepsis mortality. We investigated whether low-dose esmolol is associated with improved autophagy-related homeostasis and restored PI3K/Akt phosphorylation in SIMI.
METHODS: Human peripheral blood transcriptomic datasets (GSE28750, GSE232753, GSE134347, and GSE185263) and a rat septic myocardial dataset (GSE125042) were analyzed. Sprague-Dawley rats underwent cecal ligation and puncture (CLP) and received low-dose (5 mg·kg⁻1·h⁻1) or high-dose (15 mg·kg⁻1·h⁻1) esmolol infusion starting at 4h post-CLP. Autophagy was modulated with rapamycin, 3-methyladenine (3-MA), or chloroquine (CQ). Conscious hemodynamic monitoring, serial echocardiography, survival analysis, sepsis severity scoring, cardiac troponin I (cTnI) measurement, chamber-specific transmission electron microscopy, LC3/p62 co-localization, and TFEB subcellular localization were assessed. The unified endpoint was 18 h post-CLP.
RESULTS: Bioinformatics analyses identified Akt1 and mTOR as hub genes and highlighted PI3K/Akt signaling as a candidate pathway associated with SIMI and esmolol response. Low AKT1 expression was associated with poorer survival in septic patients and showed moderate prognostic performance (AUC = 0.750). Rat myocardial transcriptomic data showed no transcriptional suppression of PI3K/mTOR components during sepsis. Sepsis suppressed PI3K/Akt phosphorylation, with p62 and LC3-II accumulation and TFEB cytoplasmic retention. Low-dose esmolol reduced tachycardia by 15-20% without hypotension, preserved left ventricular ejection fraction, lowered cTnI (1.36 to 0.14 ng/mL) and sepsis scores (18.50 to 8.50), and improved 144 h survival (P = 0.005). High-dose esmolol caused persistent hypotension and lacked survival benefit. Low-dose esmolol partially restored PI3K/Akt phosphorylation and enhanced TFEB nuclear translocation, reduced LC3/p62 co-localization, and ameliorated chamber-specific ultrastructural damage-mitochondrial swelling in the atrium and myofibrillar disarray in the ventricle-with findings suggestive of improved autophagosome-lysosome processing. CQ aggravated myocardial injury and autophagy-marker accumulation; low-dose esmolol partially attenuated CQ-induced deterioration. Direct quantitative measurement of autophagic flux and isoform-specific functional assays targeting PI3K were not conducted in the present study.
CONCLUSIONS: Low-dose esmolol was associated with restored PI3K/Akt phosphorylation, enhanced TFEB nuclear translocation, and improved autophagy-related homeostasis in a rat SIMI model. We propose a working model in which low-dose esmolol may coordinate PI3K/Akt signaling and TFEB-mediated lysosomal adaptation to alleviate septic myocardial injury. The causal relationship cannot be definitively validated in the absence of direct flux monitoring, pathway-specific loss-of-function experiments, and isoform-specific evidence. These findings provide preclinical support for further evaluating low-dose esmolol as a candidate adjunct therapy for septic cardiomyopathy.
参考来源
- Zhang X, Fu Q, Zhang H, et al. Low-dose esmolol attenuates sepsis-induced myocardial injury: association with improved autophagic homeostasis and PI3K/Akt signaling. J Intensive Care. 2026. PMID: 42449445. doi:10.1186/s40560-026-00904-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。